A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
< 1 min read|01/08/2016
“New Age” Decision Making in HTA: Is It Applicable in Asia?
This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting in Tokyo. The panel session was entitled “New Age Decision Making in HTA: Is It Applicable in Asia?”. To open the session, David Grainger…
This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting in Tokyo. The panel session was entitled “New Age Decision Making in HTA: Is It Applicable in Asia?”. To open the session, David Grainger (Eli Lilly & Company) provided an overview of the session, offering useful background information on the topic.
“New Age” Decision Making in HTA: Is It Applicable in Asia?
Cole, A., Marsden, G., Devlin, N., Grainger, D., Lee, E.K. and Oortwijn, W.
(2016) “New Age” Decision Making in HTA: Is It Applicable in Asia?. OHE Briefing. Available from https://www.ohe.org/publications/new-age-decision-making-hta-it-applicable-asia/
Related Publications
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
